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BACKGROUND: Gene expression profiling has led to a subclassification of breast cancers independent of established clinical parameters,
such as the Sorlie–Perou subtypes. Mammographic density (MD) is one of the strongest risk factors for breast cancer, but it is
unknown if MD is associated with molecular subtypes of this carcinoma.
METHODS: We investigated whether MD was associated with breast cancer subtypes in 110 women with breast cancer, operated in
Stockholm, Sweden, during 1994 to 1996. Subtypes were defined using expression data from HGU133Aþ B chips. The MD of the
unaffected breast was measured using the Cumulus software. We used multinomial logistic models to investigate the relationship
between MD and Sorlie–Perou subtypes.
RESULTS: Although the distribution of molecular subtypes differed in women with high vs low MD, this was statistically non-significant
(P¼ 0.249), and further analyses revealed no association between the MD and Sorlie–Perou subtypes as a whole, nor with individual
subtypes.
CONCLUSION: These findings suggest that although MD is one of the strongest risk factors for breast cancer, it does not seem to be
differentially associated with breast cancer molecular subtypes. However, larger studies with more comprehensive covariate
information are needed to confirm these results.
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Mammographic density (MD) is a well-established and very strong
risk factor for breast cancer (McCormack and dos Santos Silva,
2006). Women with a percentage density (PD) of more than 75%
have a four to six times higher risk for breast cancer than women
with a PD o5% (McCormack and dos Santos Silva, 2006).
Mammographic density is defined by the relative amounts of
radiodense stromal and epithelial tissue compared with radiolu-
cent fatty tissue. Consequently, higher MD is characterised by
larger amounts of stromal and/or epithelial tissue and vice versa.
Mammographic density differs between women, as well as within
the same woman throughout her life course, being influenced by
many well-established breast cancer risk factors, such as age,
menopausal status, body mass index, hormone replacement therapy
(HRT), and parity (Boyd et al, 2009). However, the biological basis for
this association is not well understood. It has been suggested that if
MD is a marker of cumulative exposure to oestrogens, it may be
more strongly associated with oestrogen receptor (ER)-positive breast
cancers. Studies investigating this to date are highly inconsistent
(Boyd et al, 2011a; Heusinger et al, 2012; Phipps et al, 2012).
Mammographic density is radio-dense, as are tumours. Conse-
quently, density can hide tumours, a phenomenon referred to as
masking (Boyd et al, 2007). In accordance, density decreases
mammographic sensitivity (Kerlikowske et al, 1996) and is asso-
ciated with an increased risk of interval cancers (Boyd et al, 2007).
Whether the latter relationship is solely based on masking or
whether density gives rise to more highly proliferative tumours
is unknown. If the latter is true, density may be associated with
a more aggressive subtype, specifically triple-negative tumours
(ER-negative, PR-negative, and HER2-negative) and the basal
subtype (see below for description), which have been found to be
more frequent in interval cancers than screening-detected cancers
(Collett et al, 2005; Gluz et al, 2009).
Advances in microarray technology and pathology have led to
improved techniques of subclassifying tumours. Global gene
expression profiling enables a subdivision of tumours into five
individual subclasses (known as the Sorlie–Perou subtypes) found
to convey a distinct prognostic and biological message in breast
cancer above and beyond established clinical markers. The five
groups are the luminal A, luminal B, basal-like, ERBB2þ , and the
normal breast-like subtypes (Perou et al, 2000; Sorlie et al, 2003).
Luminal A tumours are mostly ER-positive, have a low prolifera-
tion rate, and are of low grade, whereas luminal B tumours are also
mostly ER-positive but may express low levels of hormone
receptors, and are usually of high grade and have a higher
proliferation rate. The basal-like subtype, on the other hand, is
often characterised by triple-negative tumours (ER-, PR-, and
HER2-negative) and a certain cytokeratin pattern, and the
ERBB2þ subtype shows amplification and high expression of
the ERBB2 gene (also known as HER2 or HER2-neu). Lastly, there
is the normal breast-like subtype, which shows expression of
many genes expressed by adipose tissue and other non-epithelial
cell types, strong expression of basal epithelial genes, and low
expression of luminal epithelial genes. It is, however, unclear
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whether the latter subtype is a distinct group or represents poorly
sampled tissue (Sorlie, 2007).
We have previously used gene expression analyses to character-
ise the genetic alterations behind tumour differentiation and p53
mutations (Miller et al, 2005; Ivshina et al, 2006). In the present
study, we explore a possible association between MD at diagnosis
and gene expression patterns from breast tumours in 110 Swedish
women operated for breast cancer, taking established prognostic
and risk factors for breast cancer into consideration.
MATERIALS AND METHODS
This is a case-only study consisting of 110 women. The source
population was all women with breast cancer operated at a large
university hospital in Stockholm between 1 January 1994 and 31
December 1996 (n¼ 524), as previously described (Pawitan et al,
2005). The women were identified through the population-based
Stockholm-Gotland Breast Cancer Registry established in 1976.
Exclusion was because of refusal of participation (n¼ 6), emigra-
tion (n¼ 7), lack of frozen tumour (n¼ 231), insufficient amount
or quality of RNA (n¼ 89), lack of gene expression profiling on
U133 A and B chips (n¼ 14), neoadjuvant therapy (n¼ 12), in situ
cancer (n¼ 5), or stage IV cancer (n¼ 1).
The subjects excluded because of lack of frozen tumour had a
lower mean tumour diameter (16mm compared with 23mm) and
fewer individuals had affected lymph nodes (16% compared with
38%) than included women. There was no difference in mean age
(57 years for both groups).
We collected information pertaining to status at diagnosis on
age, menopausal status, HRT, family history, oral contraceptive
use, and tumour characteristics from the medical records for the
remaining 159 patients. Family history includes history of breast
cancer in both first- and second-degree relatives. Menopausal status
was self-assessed by the patient as either pre- or postmenopausal.
Two women had unknown menopausal status. Both oral contra-
ceptive use and HRT use were assessed according to status at time
of referral to the Karolinska Hospital (former, current, and non-
use, collapsing former and current use into one category because
of few observations). Non-users of HRT were postmenopausal
women actively stating no current or previous use of HRT. Of the
HRT users, approximately two out of three used a combined
oestrogen and progesterone regimen, and one out of three used
oestrogen only. Local oestrogen treatment was not considered as
HRT use. Oral contraceptive use included all preparations.
The mammogram closest to diagnosis was retrieved for 141
subjects. Mammograms were digitised with an Array 2905HD Laser
Film Digitizer (Array Corporation, Hampton, NH, USA). Density
resolution was set at 12 bit, spatial resolution 5.0mm and optical
density 0–4.7. The size of the images was 4770 3580 pixels.
Tumours appear white on a mammogram and can thus distort
density measurements. As MD is highly correlated between the two
breasts (Byng et al, 1996b), we measured the mediolateral oblique
view of the breast contralateral to the tumour. Women with
bilateral breast cancer (n¼ 10) and subjects with breast implants
(n¼ 3) were excluded. We thus had density measurements for 128
women.
For all subjects, but three, date of mammography was within 1
month of the date of diagnosis. For the remaining three patients,
the mammograms collected were from 2 to 7 months before
diagnosis. Two of these patients were postmenopausal, current
HRT users at time of diagnosis, and for these two patients, we thus
lacked information on HRT status at mammography.
Assessment of MD
To measure MD, we used a computer-assisted threshold technique,
Cumulus (Byng et al, 1996a). First, the edge of the breast is
demarcated from the background, as well as from the thoracic wall
(the pectoralis muscle). Second, the observer sets the threshold
distinguishing between dense and non-dense tissue. Cumulus then
identifies all pixels as bright as, or brighter than, the threshold
level, and the absolute dense (AD) area, non-dense area, total
breast area, and PD (AD area/total breast area) are thus measured.
Two independent observers (ISS and VM) carried out the
density measurements blinded to the characteristics of the patients
and their tumours. Both observers measured all of the images and
a random repeat sample of 10% of the images. There was good
inter- and intra-observer reliability with Pearson’s correlation
coefficients of 0.82 and 0.93, respectively, for absolute density. For
our analysis, the density measurements from both observers were
averaged to minimise random measurement error.
RNA preparation and microarray profiling
Details on RNA preparation and microarray profiling have
previously been described elsewhere (Pawitan et al, 2005). Briefly,
frozen tumour was cut into minute pieces and transferred into test
tubes with RLT buffer (RNeasy lysis buffer, Qiagen, Hilden,
Germany), followed by homogenisation. Proteinase K was then
added. After this step, total RNA was isolated using Qiagen’s
microspin technology. DNase was added to some samples to
further increase RNA quality. The quality of RNA was assessed by
measuring the 28S:18S ribosomal RNA ratio.
Preparation of in vitro transcription products and oligonucleo-
tide array hybridisation and scanning were performed according to
the protocol of Affymetrix (Santa Clara, CA, USA). The molecular
subtypes have been validated previously on a larger cohort of
patients (Calza et al, 2006). As in the original publication (Sorlie,
2007), it was not possible to assign a unique subtype for all
samples. Consequently, n¼ 18 patients were excluded, leaving
n¼ 110 patients for the analyses.
Comparing the 110 individuals included in analyses with the 524
subjects from the source population reveals the following: included
individuals are almost of the same mean age as the source
population (57 compared with 58 years), but have larger tumours
(23 and 20mm, respectively) and more often present with lymph
node metastasis (38% and 26%, respectively). In other words, a
selection bias is introduced after the exclusion of women lacking
frozen tumour, but the exclusions thereafter do not change the
characteristics of the study population.
Our research was conducted under permission from the local
institutional review board.
Statistical analyses
Our main variable of interest pertaining to MD was the AD area
(measured in cm2). The association between AD and breast cancer
risk is equivalent in magnitude to the association between PD and
breast cancer risk (Vachon et al, 2007; Stone et al, 2009). We chose
to analyse AD rather than PD, owing to the lack of information on
BMI and as PD is highly, inversely correlated with BMI (through
BMI’s strong association with the non-dense area), whereas AD has
been shown to be only weakly associated with BMI (Maskarinec
et al, 2002), if at all (Haars et al, 2005). We analysed AD both as
a dichotomised (above/below median) and continuous variable
after transformation. In the latter case, we used the square-root
transformation to make the density distribution more symmetric.
The transformed density values were then standardised by
subtracting the mean and dividing by the s.d. (Z scores), to be
able to interpret the risk estimates in terms of the inherent
variability of the density values, see below.
P-values for the association between AD and patient character-
istics (age, HRT use, menopausal status, and family history) were
based on Kruskal–Wallis tests. Descriptive statistics for tumour
characteristics (i.e., tumour size, lymph node involvement, stage,
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hormone receptor status, and HER-2 status) and molecular
subtypes were compared across high- and low-density groups
using w2-tests of association and Student t-tests.
The relationship between AD and molecular subtypes was
modelled via multinomial logistic regression. The multinomial
model is an extension of the logistic regression model that allows
for more than two categories in the response variable (i.e.,
subtype). The luminal A subtype was set as reference category and
we report risk estimates as relative risk ratios (RRRs) for the
standardised, square-root-transformed AD values. The RRRs
reported in Table 3 measure the change in odds for a tumour
falling into any of the reported categories relative to the reference
category that is associated with an increase of square-root-
transformed AD by one s.d. (or somewhat less than 25% of the
range of densities).
We fitted both an age-adjusted model as well as a fully adjusted
model, which took into account known correlates of MD and
breast cancer risk (age, menopausal status, HRT, family history,
and oral contraceptive use) (Vachon et al, 2007; Boyd et al, 2011b),
and tumour size. The latter adjustment was made to try to account
for the masking bias and its possible influence on molecular
subtypes. We have no prior knowledge of whether the factors
adjusted for influence molecular subtypes, so we chose a
conservative approach. Significance testing was conducted via
likelihood ratio tests. Confidence intervals and P-values for
individual parameters are based on Wald statistics. All tests were
conducted at a nominal significance level of a¼ 0.05.
Analyses were performed using the R statistical software
environment, version 2.10.0 (R Development Core Team, 2008),
and STATA, version 11.2 (StataCorp, 2009).
RESULTS
Table 1 shows summary statistics of patient characteristics for the
whole cohort, and separately for women with low (below median)
and high (above median) AD, respectively. AD was lower in older
than younger women; women in the lowest age group (p46 years)
had a median AD of 49.2 cm2 as compared with women in the
highest age group (X69 years) whose median was 11.1 cm2
(Po0.001). Women who were current or former users of oral
contraceptives had an almost twice as large dense area as never
users of oral contraceptives (38.1, 40.6, and 22.7 cm2, respectively,
P¼ 0.022), probably also reflecting differences in parity and age at
first birth, information which we lacked. Postmenopausal women
had lower AD than premenopausal women (43.6 cm2 compared
with 18.1 cm2, Po0.001; Table 1). In postmenopausal women,
current HRT users had higher AD than past and never users (23.6,
13.2.0, and 13.2 cm2, respectively, P¼ 0.029; Table 1).
Table 2 shows the distributions of clinical parameters and
molecular subtypes in the study population, and separately for
women with low AD and those with high AD. No statistically
significant associations were seen. However, in comparison with
tumours diagnosed in low AD breasts, tumours diagnosed in high
AD breasts tended to more often be ER-positive (69% compared
with 60%, P¼ 0.065) and PR-positive (76% compared with 62%,
P¼ 0.099). The luminal A and normal breast-like subtypes were
the most common subtypes in the population as a whole (27%
each), whereas the luminal A subtype was the most common
subtype in women with low AD breasts (36%), and the normal
breast-like subtype was most common in women with high AD
breasts (33%; P¼ 0.249).
Compared with the luminal A subtype (taken as the reference
category), the relative risk of the luminal B, ERBB2, and normal
breast-like subtypes increased with increasing AD both in the age-
adjusted (RRR 1.19, 95% CI 0.58–2.45; RRR 1.88, 95% CI 0.79–4.48;
and RRR 1.51, 95% CI 0.78–2.92, respectively, for an increase in
Table 1 Patient characteristics at time of diagnosis and AD, reported as
median (1st quartile to 3rd quartile)
n AD P-value
Age (years) o0.001
32–46 26 49.2 (38.3–67.4)
47–55 26 37.5 (19.3–53.2)
56–68 29 27.1 (14.9–40.6)
69–86 29 11.1 (3.9–19.9)
Oral contraceptive use 0.022
Current 4 38.1 (33.7–42.9)
Never 71 22.7 (10.5–48.2)
Former 25 40.6 (29.4–42.2)
Menopause o0.001
Premenopausal 39 43.6 (35.3–67.4)
Postmenopausal 69 18.1 (9.5–33.1)
Unknown 2 20.5 (11.6–29.4)
HRT use 0.029
Current 23 23.6 (15.5–41.7)
Never 34 13.2 (5.5–29.0)
Former 8 13.2 (7.4–21.6)
Family history 0.231
Yes 24 27.0 (10.6–39.7)
No 84 31.7 (15.5–47.4)
Abbreviations: AD¼ absolute dense area; HRT¼ hormone replacement therapy.
P-values are based on a Kruskal–Wallis test.
Table 2 Distribution of tumour characteristics for the whole study
population and separately by AD level (below/above median)
All
(n¼ 110)
Low AD
(n¼ 55)
High AD
(n¼ 55) P-value
Tumour size (mm) 22.9 (1.1) 22.6 (1.6) 23.1 (1.7) 0.821
Lymph node metastasis 0.379
Yes (%) 38 (36) 21 (40) 17 (31)
No (%) 69 (64) 32 (60) 37 (69)
ER statusa 0.065
Positive (%) 86 (78) 39 (71) 47 (85)
Negative (%) 24 (22) 16 (29) 8 (15)
PR statusa 0.099
Positive (%) 34 (31) 34 (62) 42 (76)
Negative (%) 76 (69) 21 (38) 13 (24)
HER2 statusb 0.973
Positive (%) 15 (18) 7 (18) 8 (18)
Negative (%) 70 (82) 33 (83) 37 (82)
Stage 0.237
1 (%) 45 (42) 18 (34) 27 (50)
2 (%) 24 (22) 14 (26) 10 (19)
3 (%) 38 (36) 21 (40) 17 (31)
4 (%) 0 (0) 0 (0) 0 (0)
Molecular subtype 0.249
Luminal A (%) 30 (27) 20 (36) 10 (18)
Luminal B (%) 19 (17) 8 (15) 11 (20)
Basal-like (%) 19 (17) 10 (18) 9 (16)
ERBB2 (%) 12 (11) 5 (9) 7 (13)
Normal breast-like (%) 30 (27) 12 (22) 18 (33)
Abbreviations: AD¼ absolute dense area; ER¼ oestrogen receptor. Summary
statistics are given as mean (s.e.) and count (%), respectively. P-values are based
on t-tests and w2-tests comparing tumour characteristics in women with low and
high AD. aPositive if X0.05 fmol receptor per mg DNA. bPositive if score X2
according to immunohistochemistry.
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square-root-transformed density by one s.d.) and in the fully
adjusted (RRR 1.22, 95% CI 0.53–2.83; RRR 1.74, 95% CI 0.62–4.85;
and RRR 1.43, 95% CI 0.64–3.17, respectively) models (Table 3).
The relative risk of the basal subtype was essentially the same as
that of the luminal A subtype in the age-adjusted model (RRR 0.99,
95% CI 0.48–2.06), but decreased with increasing AD in the fully
adjusted model (RRR 0.83, 95% CI 0.33–2.10) (Table 3). None of
the individual associations were, however, statistically significant,
nor was the association between AD and molecular subtype as a
whole statistically significant (P¼ 0.483 and P¼ 0.651 for the age-
adjusted and fully adjusted models, respectively).
DISCUSSION
To our knowledge, no previous studies have investigated the relation-
ship between MD and molecular subtypes using gene expression data.
We found no associations between AD and Sorlie–Perou subtypes;
neither between AD and individual subtypes, nor between AD and
subtype as a whole. However, our study population was relatively
small and the null findings could simply be because of low power.
Hence, larger studies are needed to confirm our results.
A couple of studies have previously attempted to investigate the
association between MD and Sorlie–Perou subtypes using receptor
status (ER-, PR-, and HER2 status) as proxies for the different
molecular subtypes (Ma et al, 2009; Arora et al, 2010; Phipps et al,
2012). Ma et al (2009) studied the association between PD and the
luminal A and basal-like subtypes, and found no association in
case-only analyses. In case–control analyses, they observed
positive associations between PD, and both the luminal A and
basal-like subtypes, but as these associations were of a similar
magnitude, they are likely to simply reflect the general increase in
breast cancer risk associated with PD. Phipps et al (2012) also
conducted a case–control study investigating the association
between density (assessed using a visual categorical classification,
BI-RADS), ERþ , ER /PR /HER2þ , and triple-negative breast
cancers. They achieved the same results as Ma et al (2009), that is,
the density was similarly, positively associated with all subtypes.
They concluded that although the different subtypes are distinct
biological entities, this is not a result of differences in the
association with MD. We thus believe that our results are in
agreement with both studies. Arora et al (2010) studied the
association between density and the luminal A, luminal B, basal-
like, and ERBB-2 subtypes, also using BI-RADS to assess density.
They observed that women with extremely dense breasts had a
higher frequency of luminal A tumours (P¼ 0.05). However, as
only age was adjusted for in this analysis, the findings might have
been affected by residual confounding.
According to a recent review, most studies have found no associa-
tion between MD, tumour size, lymph node metastasis, and hormone
receptor status, respectively (Boyd et al, 2011a). The two published
studies investigating the relationship between MD and HER2 status
also found no association (Yaghjyan et al, 2011; Heusinger et al,
2012) as did one of two studies on density and survival (Chiu et al,
2010). We find this to be in indirect support of the null association
between MD and Sorlie–Perou subtypes shown in this study, as
molecular subtypes are associated with both tumour characteristics
and prognosis (Sorlie et al, 2001; Sotiriou et al, 2003).
In contrast to our null findings, two large, recently published
studies showed a positive association between PD and ER-negative
cancers (Yaghjyan et al, 2011), and an association between PD and
decreased ER expression (Heusinger et al, 2012), respectively,
which could indirectly point to an association with the basal
subtype. However, the former study (Yaghjyan et al, 2011) had a
possibly biased study sample with a very large amount of HRT
users (76% of cases) and women with previous benign breast
disease (59%). These are both associated with MD (Byrne et al,
2000; Vachon et al, 2007) and interval cancer status (Brekelmans
et al, 1994; Kavanagh et al, 2000); the latter in turn associated with
triple-negative disease (Gluz et al, 2009). Neither mode of
detection nor tumour size was adjusted for to try to account for
this. The latter study (Heusinger et al, 2012) showed a statistically
significant association between PD and lower ER expression.
However, the group with an ER expression of 10–69% (considered
ER-positive) had the highest PD and were not statistically different
from the group with 0–9% expression, referred to as the ER-
negative group. Thus, although interesting, we cannot directly
apply these results to the ER status.
A limitation of our study was the selection of larger tumours,
and thus, tumours of higher stage than that of the source
population, because of the harvest of RNA requiring a certain
amount of tumour tissue. This may have given rise to a more
homogeneous population pertaining to variables associated with
stage, which may have influenced the null associations between AD
and molecular subtypes. However, as the analysis of molecular
subtypes requires RNA, this was unfortunately inevitable.
We used AD as a measure of density instead of PD, as we lacked
information on BMI. The BMI is highly, inversely correlated with
PD through its association with the non-dense area, whereas AD
has not been shown to be associated with BMI (Haars et al, 2005),
or to a much lesser extent (Maskarinec et al, 2002). Both measures
are equally predictive of breast cancer risk (Vachon et al, 2007;
Stone et al, 2009; Stone et al, 2010). Whether AD or PD is a more
appropriate measure of density in relation to molecular subtype is,
to our knowledge, not known. The benefit of AD compared with
PD is that it is an absolute estimate of density, whereas PD is a
relative estimate; a woman with x amount of dense tissue in a small
breast will have a higher PD than a woman with the same amount
of dense tissue in a larger breast. As our findings on the
association between AD and molecular subtypes are in agreement
with most studies on related outcomes (tumour characteristics and
survival; Chiu et al, 2010; Boyd et al, 2011a) where density was
either measured as PD or visually categorised, we do not believe
that the use of AD has weakened our study. However, the fatty
tissue of the breast is an important contributor of local oestrogens
(Thijssen, 2004) and could thus influence tumour subtype. Hence,
we also carried out analyses adjusting for the non-dense area,
based on results from a study by Lokate et al (2011), showing that
AD adjusted for the non-dense area was an even better model for
breast cancer risk prediction than both PD and AD adjusted for
BMI. Adjustment for the non-dense area did not, however, change
the interpretation of our results (data not shown).
We used the density measurements of the breast contralateral to the
tumour to avoid a distortion of measurements due to the tumour itself.
Table 3 RRRs for specific molecular subtypes of breast cancer compared
with the luminal A subtype for an increase in square-root-transformed AD
by one s.d.
Age-adjusteda Fully adjustedb
RRR 95% CI P-value RRR 95% CI P-value
Subtype
Luminal A 1.00 (ref.) 1.00 (ref.)
Luminal B 1.19 0.58–2.45 0.641 1.22 0.53–2.83 0.644
Basal-like 0.99 0.48–2.06 0.986 0.83 0.33–2.10 0.690
ERBB2 1.88 0.79–4.48 0.153 1.74 0.62–4.85 0.291
Normal
breast-like
1.51 0.78–2.92 0.222 1.43 0.64–3.17 0.385
Abbreviations: AD¼ absolute dense area; CI¼ confidence interval; HRT¼ hormone
replacement therapy; RRR¼ relative risk ratios. aAdjusted for age; P¼ 0.483 for
the association between AD and subtype as a whole based on the likelihood ratio
test. bAdjusted for age, oral contraceptive use, menopausal status, HRT use, family
history, tumour size; P¼ 0.651 for the association between AD and subtype as a
whole, based on the likelihood ratio test.
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We believe that these measurements are a reliable proxy of the pre-
diagnostic level of density of the affected breast, as MD has been shown
to be highly correlated between the two breasts (Byng et al, 1996b) and
mammograms were taken before any breast cancer treatment. Density
assessment was carried out using a semi-automated computer software
minimising exposure misclassification (Vachon et al, 2007).
CONCLUSIONS
Our findings suggest that although MD is one of the strongest risk
factors for breast cancer, it does not seem to differentially
influence molecular subtype. However, our results should be
confirmed in a larger study with more comprehensive information
on breast cancer risk factors.
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